Luxembourg, 28 March 2019 – IBBL (Integrated BioBank of Luxembourg) is pleased to announce the positive results of its new Proficiency Testing programme in China. The values indicate an encouraging consistency between the measurements obtained by the Chinese and international participants, pointing towards an increasing standardisation of biobanking and laboratory practices worldwide.
In the wake of the success of IBBL’s international Proficiency Testing (PT) programme, a new PT programme entirely dedicated to Chinese biobanks was launched in July 2018, in an agreement between IBBL, the International Society for Biological and Environmental Repositories (ISBER) and the Biobank Branch, China Medicinal Biotech Association (BBCMBA). The one-year pilot programme offered two testing schemes: ‘DNA quantification and purity’ and ‘RNA quantification and purity’. About 30 participants enrolled for each scheme.
The assigned values obtained by the Chinese institutions for both the ‘DNA quantification and purity’ and ‘the RNA quantification and purity’ schemes were found to be almost identical to those obtained by the rest of the international participants.
“These results demonstrate that the performance of the biospecimen testing methods of Chinese biobanks and testing laboratories is in line with that of our international colleagues, and that the measurements obtained by Chinese institutions can therefore be considered trustworthy and of high quality”, states Prof Gao, President of BBCMBA. “This will further contribute to enhancing data exchanges between China and international laboratories, thus strengthening cooperation and supporting the development of global health”, he adds.
“We are very pleased with the outcome of the pilot, since it marks a step forward in terms of biospecimen quality and standardisation of biobanking practices worldwide”, declares Dr. Fay Betsou, Chief Scientific Officer at IBBL. “This is particularly relevant when considering that participation in PT programmes is a requirement for biobanks seeking accreditation according to the new ISO 20387 norm”, she adds.
“ISBER is committed to supporting biorepositories globally, and the PT programme in China has proved to be a valuable tool in this respect. The interest and participation of the Chinese biobanking community in the pilot have been very promising and we sincerely hope to witness an increased adherence of Chinese organisations to the programme in the coming years”, says Dr Xun Xu, ISBER Director at Large for China.
As the sole ISBER-endorsed PT programme in the world that focuses on biospecimens, IBBL’s processing and testing schemes have become increasingly popular over the years. In 2018, 115 participants from 31 countries registered for a total of 492 subscribed processing and testing schemes.
For more information, please visit the dedicated IBBL PT webpage.